Clinical Trial Update: Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 [Phase 1]

View source ↗

Summary

Phase 1 hAME study assessing absorption, distribution, and metabolism of [14C]-KD025 in autoimmune diseases and fibrosis; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Diseases
• Fibrosis

Drugs mentioned

• KD025

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Autoimmune Diseases, Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2021-09-13